BT-GSI

BT-GSI is a γ-secretase inhibitor (GSI) and a bone-targeted Notch inhibitor. BT-GSI has dual anti-myeloma and anti-resorptive properties, which can be used for the research of multiple myeloma and associated bone disease. BT-GSI inhibits tumor growth and osteolytic disease progression[1].

Product Specifications

UNSPSC

12352005

Target

Notch; γ-secretase

Type

Reference compound

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/bt-gsi.html

Solubility

10 mM in DMSO

Smiles

O=P(O)(O)C(P(O)(O)=O)NC(CCCN(C)/N=C/[C@H](CC(C)C)NC([C@H]([C@@H](C)CC)NC(OCC1=CC=CC=C1)=O)=O)=O.Br

Molecular Formula

C26H46BrN5O10P2

Molecular Weight

730.52

References & Citations

[1]Hayley M Sabol, et al. Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity. Cancer Res. 2021 Oct 1;81 (19) :5102-5114.